Dilution profile // every instrument, one screen, from SEC filings

Jazz Pharmaceuticals plc (JAZZ)

CIK 1232524 · all EDGAR filings →

Overall dilution risk
LOWworst of 4 computed signals (offering ability)
= the worst band among the computed sub-ratings, no hidden weighting
Offering ability
LOWno live registration found
= is there a registration (S-1/S-3 family) on file without a later withdrawal
Overhead supply
LOWwarrants = 2% of O/S
= warrant shares outstanding divided by current shares outstanding (bands: 20% / 50%)
warrants only; converts, ATMs and equity lines are not in free structured data, so the true overhead is AT LEAST this
Historical dilution
LOW+3% O/S in 3y
= share count now vs 3 years ago (bands: 30% / 100%); a reverse split pushes this negative
Cash need
LOWoperating cash flow positive
= cash vs trailing operating burn (bands: 6mo / 24mo; positive operating CF = low)

Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.

Shares outstanding over time

2022-02-222026-07-27

Latest: 64.9M shares as of Jul 27, 2026 (10-Q).

Cash runway

Self-funding

generates cash

Full breakdown: cash runway tool · source filing →

Warrants

Warrants outstanding: 1.6M underlying shares, as reported Dec 31, 2013 (10-K).

Rough fully diluted estimate: 66.5M = 64.9M O/S + 1.6M warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.

Convertible notes

NotePrincipalCarryingConv. priceRateIf converted
Exchangeable Senior Notes Due 2030not tagged$1.00B$153.05
Exchangeable Senior Notes Due 2026not tagged$0$155.81

Notes exactly as the company dimensioned them in its 10-Q filed Aug 3, 2026. Principal is face amount as tagged, not what remains after repurchases unless the filer updated the tag. A note the filer did not dimension is absent here, not absent from the balance sheet; the exhibits stay the ground truth.

Fully diluted build-up

Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.

Shares outstanding64.9MJul 27, 2026
+ Warrants (aggregate, as tagged) (if exercised)1.6MDec 31, 2013
Fully diluted estimate66.5M+2.4% vs O/S

Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.

Registrations and offerings

Last 12 months: 0 executed · 0 registered.

EXECUTEDSep 6, 2024Unregistered share sale disclosed (8-K item 3.02)8-K
EXECUTEDMay 5, 2021Unregistered share sale disclosed (8-K item 3.02)8-K
EXECUTEDJun 11, 2020Unregistered share sale disclosed (8-K item 3.02)8-K
EXECUTEDSep 1, 2017Unregistered share sale disclosed (8-K item 3.02)8-K
EXECUTEDAug 23, 2017Unregistered share sale disclosed (8-K item 3.02)8-K

Full history and shelf status: offering checker · S-3 shelf checker

Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.

Keep going: float checker · offering calendar · short-squeeze screener · full JAZZ workspace